Finally!!! It's about time we saw some Alcon dollars in the dry eye drug research world.

First, we've got cilomilast, which I've never even heard of in this context. Alcon are licensing it from GlaxoSmithKline for ophthalmic indications.

Then, we've got a closer relationship with Origenis:

Alcon expanded its existing drug research alliance with Origenis with a focus on the discovery and development of the small molecules that might one day have a role in the treatment of eye diseases.

Here's the whole article if you're interested:

Alcon Pads Eye-Disease Pipeline through Deals with GSK and Origenis